Horizon Therapeutics Public Limited Company (HZNP) Financials

NASDAQ Currency in USD Disclaimer

$116.30

north_east NA Past Year
Day's range
$116.3
Day's range
$116.34
$4B$4B$3B$3B$2B$2B$1B$1B$0$0-$1B-$1BEarning2016201620172017201820182019201920202020202120212022202260%60%40%40%20%20%0%0%-20%-20%-40%-40%Profit Margin
Profit Margin
Revenue
Earnings

HZNP Income statement / Annual

Last year (2022), Horizon Therapeutics Public Limited Company's total revenue was $3.63 B, an increase of 12.48% from the previous year. In 2022, Horizon Therapeutics Public Limited Company's net income was $521.48 M. See Horizon Therapeutics Public Limited Company,s key income statements, including revenue, expenses, profit, and income.

Period FY-2022 FY-2021 FY-2020 FY-2019 FY-2018 FY-2017 FY-2016 FY-2015 FY-2014 FY-2013
Period Ended 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014 12/31/2013
Operating Revenue $3.63 B $3.23 B $2.20 B $1.30 B $1.21 B $1.06 B $981.12 M $757.04 M $296.96 M $74.02 M
Cost of Revenue $920.20 M $794.51 M $532.70 M $362.18 M $422.32 M $546.28 M $393.27 M $219.50 M $78.75 M $14.63 M
Gross Profit $2.71 B $2.43 B $1.67 B $937.85 M $785.25 M $509.96 M $587.85 M $537.54 M $218.20 M $59.39 M
Gross Profit Ratio 0.75 0.75 0.76 0.72 0.65 0.48 0.6 0.71 0.73 0.8
Research and Development Expenses $437.96 M $431.99 M $209.36 M $103.17 M $82.76 M $224.96 M $60.71 M $41.87 M $17.46 M $10.08 M
General & Administrative Expenses $1.54 B $0.00 $0.00 $0.00 $0.00 $0.00 $287.94 M $219.86 M $88.96 M $23.57 M
Selling & Marketing Expenses $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $320.37 M $220.44 M $120.28 M $68.60 M
Selling, General & Administrative Expenses $1.54 B $1.45 B $973.23 M $697.11 M $692.49 M $677.36 M $608.31 M $440.31 M $209.23 M $92.16 M
Other Expenses -$5.57 M $1.79 M $3.39 M -$944,000.00 $346,000.00 $588,000.00 $6.70 M -$10.29 M -$11.25 M $0.00
Operating Expenses $1.98 B $1.88 B $1.18 B $800.28 M $775.25 M $902.33 M $669.02 M $482.17 M $226.69 M $102.25 M
Cost And Expenses $2.90 B $2.67 B $1.72 B $1.16 B $1.20 B $1.45 B $1.06 B $701.67 M $305.45 M $116.87 M
Interest Income $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Interest Expense $83.71 M $81.06 M $59.62 M $87.09 M $121.69 M $126.52 M $86.61 M $69.90 M $23.83 M $39.18 M
Depreciation & Amortization $497.25 M $365.91 M $277.96 M $247.18 M $275.73 M $283.42 M $221.84 M $138.34 M $34.01 M $9.31 M
EBITDA $1.11 B $909.04 M $767.98 M $373.79 M $286.08 M -$108.37 M $147.37 M $55.37 M -$8.49 M -$42.85 M
EBITDA Ratio 0.31 0.28 0.35 0.29 0.24 -0.1 0.15 0.24 0.05 -0.45
Operating Income Ratio 0.17 0.17 0.22 0.1 0 -0.37 -0.15 0.07 -0.03 -0.58
Total Other Income/Expenses Net -$90.48 M -$80.30 M -$88.38 M -$146.84 M -$121.54 M -$120.91 M -$80.92 M -$188.08 M -$261.20 M -$107.27 M
Income Before Tax $526.94 M $462.83 M $401.65 M -$20.22 M -$119.15 M -$513.28 M -$228.09 M -$132.71 M -$269.69 M -$150.13 M
Income Before Tax Ratio 0.15 0.14 0.18 -0.02 -0.1 -0.49 -0.23 -0.18 -0.91 -2.03
Income Tax Expense $5.45 M -$71.66 M $11.85 M -$593.24 M -$44.96 M -$102.75 M -$61.25 M -$172.24 M -$6.08 M -$1.12 M
Net Income $521.48 M $534.49 M $389.80 M $573.02 M -$74.19 M -$410.53 M -$166.83 M $39.53 M -$263.60 M -$149.01 M
Net Income Ratio 0.14 0.17 0.18 0.44 -0.06 -0.39 -0.17 0.05 -0.89 -2.01
EPS 2.28 2.37 1.91 3.13 -0.45 -2.52 -1.04 0.27 -3.15 -2.34
EPS Diluted 2.22 2.27 1.81 2.9 -0.45 -2.52 -1.04 0.25 -3.15 -2.34
Weighted Average Shares Out $229.11 M $225.55 M $215.31 M $205.22 M $166.16 M $163.12 M $160.70 M $148.79 M $83.75 M $63.66 M
Weighted Average Shares Out Diluted $235.24 M $235.68 M $215.31 M $205.22 M $166.16 M $163.12 M $160.70 M $155.92 M $83.75 M $63.66 M
Link